Direct renin inhibitor (aliskiren) and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy

Trial Profile

Direct renin inhibitor (aliskiren) and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy

Suspended
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2013

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms APSHA
  • Most Recent Events

    • 15 Sep 2012 Status changed from recruiting to suspended as reported by European Clinical Trials Database record.
    • 04 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top